Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users

AIDS

Volumn 26, Issue 18, 2012, Pages 2383-2391

  Fu, Tsung Chieh ^a   Westergaard, Ryan P ^b   Lau, Bryan ^c   Celentano, David D ^c   Vlahov, David ^d   Mehta, Shruti H ^c   Kirk, Gregory D ^a,c,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; HIV prevention; injecting; injection drug users; risk compensation; sexual behavior

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ALCOHOL ABUSE; ARTICLE; BEHAVIOR CHANGE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG ABUSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; UNITED STATES; UNSAFE SEX; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BALTIMORE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMMUNITY HEALTH SERVICES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEEDLE SHARING; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; UNSAFE SEX; VIRAL LOAD;

EID: 84870244817     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835ad438     Document Type: Article

References (48)

1. Detels R, Munoz A, McFarlane G, Kingsley L, Margolick J, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860. (Pubitemid 28135961)
3. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006;194:11-19.
4. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007;146:591-601. (Pubitemid 351650540)
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
6. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010;50(Suppl 3):S85-S95.
7. Montaner JS. Treatment as prevention-a double hat-trick. Lancet 2011;378:208-209.
8. Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001;15:1287-1294. (Pubitemid 32592362)
9. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006;3:e124.
10. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009;373:48-57.
11. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002;2:487-493. (Pubitemid 34826854)
12. Kalichman S, Eaton L, Pinkerton S. Circumcision for HIV prevention: failure to fully account for behavioral risk compensation. PLoS Med 2007;4:e138.
13. Newman PA, Roungprakhon S, Tepjan S, Yim S. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 2010;28:958-964.
14. Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, Chen PL, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis 2008;35:1002-1008.
15. Dukers NHTM, Goudsmit J, de Wit JBF, Prins M, Weverling G-J, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 2001;15:369-378. (Pubitemid 32163823)
16. Tun W, Gange SJ, Vlahov D, Strathdee SA, Celentano DD. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIVinfected injection drug users. Clin Infect Dis 2004;38:1167-1174. (Pubitemid 38951266)
17. Ostrow DE, Fox KJ, Chmiel JS, Silvestre A, Visscher BR, Vanable PA, et al. Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS 2002;16:775-780. (Pubitemid 34274468)
18. Tun W, Celentano DD, Vlahov D, Strathdee SA. Attitudes toward HIV treatments influence unsafe sexual and injection practices among injecting drug users. AIDS 2003;17:1953-1962. (Pubitemid 37070281)
19. Hayden E. 'Seek, test and treat' slows HIV. Nature 2010;463:1006.
20. Montaner J, Wood E, Kerr T, Lima V, Barrios R, Shannon K, et al. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndr 2010;55:S5-S9.
21. Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, Gibson S, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002;92:388-394. (Pubitemid 34184826)
22. Rietmeijer CA. Resurgence of risk behaviors among men who have sex with men: the case for HAART realism. Sex Transm Dis 2005;32:176-177. (Pubitemid 40271270)
23. Stolte IG, Dukers NHTM, de Wit JBF, Fennema JSA, Coutinho RA. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Infect 2001;77:184-186. (Pubitemid 32595739)
24. Stolte IG, Dukers NHTM, Geskus RB, Coutinho RA, de Wit JBR. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: A longitudinal study. AIDS 2004;18:303-309. (Pubitemid 38253454)
25. Optimism ICOH. HIV treatments optimism among gay men: an international perspective. J Acquir Immune Defic Syndr 2003;32:545-550.
26. Venkatesh KK, Flanigan TP, Mayer KH. Is expanded HIV treatment preventing new infections?Impact of antiretroviral therapy on sexual risk behaviors in the developing world. AIDS 2011;25:1939-1949.
27. Wandera B, Kamya MR, Castelnuovo B, Kiragga A, Kambugu A, Wanyama JN, et al. Sexual behaviors over a 3-year period among individuals with advanced HIV/AIDS receiving antiretroviral therapy in an urban HIV clinic in Kampala, Uganda. J Acquir Immune Defic Syndr 2011;57:62-68.
28. Venkatesh KK, de Bruyn G, Lurie MN, Mohapi L, Pronyk P, Moshabela M, et al. Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. AIDS 2010;24:2687-2696.
29. Bouhnik AD, Moatti JP, Vlahov D, Gallais H, Dellamonica P, Obadia Y. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. J Epidemiol Commun Health 2002;56:349-353. (Pubitemid 34454560)
30. Marshall B, Milloy M, Kerr T, Zhang R, Montaner J, Wood E. No evidence of increased sexual risk behaviour after initiating antiretroviral therapy among people who inject drugs. AIDS 2010;24:2271-2278.
31. Kuyper L, Milloy MJ, Marshall BD, Zhang R, Kerr T, Montaner JS, et al. Does initiation of HIV antiretroviral therapy influence patterns of syringe lending among injection drug users? Addict Behav 2011;36:560-563.
32. Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. Addiction 2006;101:433-440. (Pubitemid 43344826)
33. Vlahov D, Safaien M, Lai S, Strathdee SA, Johnson L, Sterling T, et al. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS 2001;15:2311-2316. (Pubitemid 34059839)
34. Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: Plasma viral load and CD4R cell count. JAMA 1998;279:35-40. (Pubitemid 28070548)
35. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: Description of methods and characterisitics of participants. NIDA Res Monograph 1991;109:75-100. (Pubitemid 23095616)
36. Macalino GE, Celentano DD, Latkin C, Strathde SA, Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prevent 2002;14:367-1367.
37. Celentano DD, Galai N, Sethi AK, Shah NGA, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001;15:1707-1715. (Pubitemid 32918126)
38. Mehta SH, Lucas G, Astemborski J, Kirk GD, Vlahov D, Galai N. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care 2007;19:637-645. (Pubitemid 46763739)
39. Kavasery R, Galai N, Astemborski J, Lucas GM, Celentano DD, Kirk GD, et al. Nonstructured treatment interruptions among injection drug users in Baltimore, MD. J Acquir Immune Defic Syndr 2009;50:360-366.
40. Morris J, Golub E, Mehta S, Jacobson L, Gange S. Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther 2007;4:12.
41. Marshall BD, Milloy MJ, Kerr T, Zhang R, Montaner JS, Wood E. No evidence of increased sexual risk behaviour after initiating antiretroviral therapy among people who inject drugs. AIDS 2010;24:2271-2278.
42. Bouhnik AD, Carrieri MP, Rey D, Spire B, Gastaut JA, Gallais H, et al. Drug injection cessation among HIV-infected injecting drug users. Addict Behav 2004;29:1189-1197. (Pubitemid 38962347)
43. Lindenburg CEA, Krol A, Smit C, Buster MCA, Coutinho RA, Prins M. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS 2006;20:1771-1775. (Pubitemid 44299369)
44. Metsch LR, Pereyra M, Purcell DW, Latkin CA, Malow R, Gomez CA, et al. Correlates of lending needles/syringes among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr 2007;46(Suppl 2):S72-S79. (Pubitemid 350293783)
45. Latkin CA, Buchanan AS, Metsch LR, Knight K, Latka MH, Mizuno Y, et al. Predictors of sharing injection equipment by HIV-seropositive injection drug users. J Acquir Immune Defic Syndr 2008;49:447-450.
46. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries. JAMA 2000;283:1175-1182.
47. Attia S, Egger M, Mueller M, Zwahlen M, Low N. Sexual transmission of HIVaccording to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009;23:1397-1404.
48. Donnell K, Kiarie J, Thomas K. ART and risk of heterosexual HIV-1 transmission in HIV-1 serodiscordant African couples: a multinational prospective study. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2010.